NCT02481453View on ClinicalTrials.gov

Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
Inclusion Body Myositis (IBM)
Interventions
DRUG

Rapamycin

Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo

DRUG

Placebo

Comparator: placebo

Trial Locations (1)

75651

CIC Paris Est _Hôpital Pitié Salpêtrière, Paris

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02481453 - Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis | Biotech Hunter | Biotech Hunter